NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Motilal Oswal has raiseed its earnings estimates on Indegene Ltd. considering the impact of new deals and the possibility of increased work outsourcing from the global pharma and life sciences companies amid expanding drug pipelines, rising clinical trial activity, and increasing regulatory complexity for life sciences companies.
The brokerage expects Indegene to deliver a compound annual growth rate of 19%/21%/18% in revenue/Ebit/PAT over FY25-28.
Motilal Oswal reiterates its Neutral rating with a revised target price of Rs 552 (based on 20x FY28E earnings per share).
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
